Home » Stocks » XOMA

XOMA Corporation (XOMA)

Stock Price: $32.50 USD -0.53 (-1.60%)
Updated November 24, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 358.22M
Revenue (ttm) 2.23M
Net Income (ttm) -12.71M
Shares Out 11.02M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $32.50
Previous Close $33.03
Change ($) -0.53
Change (%) -1.60%
Day's Open 33.28
Day's Range 31.50 - 33.65
Day's Volume 18,366
52-Week Range 14.14 - 34.00

More Stats

Market Cap 358.22M
Enterprise Value 342.90M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 11.02M
Float 10.41M
EPS (basic) -1.31
EPS (diluted) -1.26
FCF / Share -1.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 583,638
Short Ratio 23.02
Short % of Float 5.61%
Beta 0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 160.85
PB Ratio 9.47
Revenue 2.23M
Operating Income -15.46M
Net Income -12.71M
Free Cash Flow -11.74M
Net Cash 15.32M
Net Cash / Share 1.39
Gross Margin 768.96%
Operating Margin -694.07%
Profit Margin -570.80%
FCF Margin -527.30%
ROA -10.59%
ROE -42.89%
ROIC -21.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.50*
(-9.23% downside)
Low
29.0
Current: $32.50
High
30.0
Target: 29.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue18.375.3052.695.5655.4518.8735.4533.7858.2033.64
Revenue Growth246.67%-89.94%846.98%-89.97%193.9%-46.78%4.94%-41.95%72.99%-
Gross Profit18.375.3052.695.5655.4518.8735.4533.7858.2033.64
Operating Income-3.89-16.8617.03-61.56-39.72-81.83-58.21-56.62-33.96-67.10
Net Income-1.98-13.3414.60-53.53-20.61-38.30-124-71.07-32.74-68.76
Shares Outstanding8.768.377.626.025.895.374.353.231.580.93
Earnings Per Share-0.23-1.590.73-8.89-3.50-13.49-28.60-22.00-20.80-73.80
Operating Cash Flow-0.29-12.642.69-33.69-30.89-78.28-45.92-40.77-29.06-52.54
Capital Expenditures-19.30-15.011.61-0.01-0.41-0.33-1.17-2.05-3.30-0.34
Free Cash Flow-19.59-27.654.29-33.70-31.30-78.61-47.08-42.81-32.37-52.88
Cash & Equivalents56.6945.7843.4725.7466.2678.4512285.3348.3437.30
Total Debt32.8522.4814.5743.1748.6735.3140.9941.0436.3213.69
Net Cash / Debt23.8423.3028.90-17.4317.6043.1480.6644.2912.0223.61
Assets95.7263.7944.9428.6874.8889.4013510678.0474.25
Liabilities51.7445.0039.1575.8977.1986.3013984.2163.0350.66
Book Value43.9918.795.79-47.21-2.313.10-3.9921.4715.0123.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name XOMA Corporation
Country United States
Employees 11
CEO James R. Neal

Stock Information

Ticker Symbol XOMA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XOMA

Description

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.